The Klow Blend is a full-spectrum recovery peptide stack combining four of the most well-researched tissue-repair and anti-inflammatory compounds in a single 80mg vial: GHK-Cu, BPC-157, Thymosin Beta-4 (TB4/TB-500), and KPV. For researchers studying musculoskeletal recovery, inflammation resolution, and systemic tissue remodelling, this pre-formulated blend eliminates the need to source, reconstitute, and dose four separate peptides — while maintaining 99% HPLC-verified purity across all components.
This guide covers the mechanism of each compound, the scientific rationale for stacking them, dosing considerations, and how to source the Klow Blend in India.
What Is the Klow Blend?
The Klow Blend is Peptide Central's signature recovery stack, formulated to address multiple overlapping axes of tissue repair and immune modulation simultaneously. The four peptides in the blend — GHK-Cu, BPC-157, Thymosin Beta-4 (TB4), and KPV — represent distinct mechanistic classes that research has shown to be complementary rather than redundant.
Each compound in the blend targets a different phase or pathway of the repair cascade: GHK-Cu drives extracellular matrix remodelling and growth factor upregulation; BPC-157 accelerates local tissue repair through angiogenesis and fibroblast recruitment; TB4 provides systemic anti-inflammatory and cell migration support; and KPV directly suppresses pro-inflammatory cytokine signalling. Together, they cover the full spectrum from acute inflammation resolution through to structural tissue rebuilding.
The Klow Blend is available as an 80mg lyophilised powder vial at ₹6,999 (originally ₹11,999), representing a significant cost saving versus purchasing each peptide individually. All components are independently HPLC-verified and a Certificate of Analysis (COA) is included with every order.
The Four Compounds Explained
GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper-binding tripeptide (Gly-His-Lys) found in human plasma, saliva, and urine, where circulating concentrations decline sharply with age — from approximately 200 ng/mL at age 20 to under 80 ng/mL by age 60. This age-dependent decline correlates with reduced wound healing capacity, skin thinning, and impaired tissue remodelling.
Mechanistically, GHK-Cu activates over 30 genes involved in collagen and glycosaminoglycan synthesis, upregulates growth factors including TGF-β1, VEGF, and FGF, and exerts potent antioxidant activity by chelating free copper ions and inducing superoxide dismutase expression. In the context of a recovery stack, GHK-Cu is the primary driver of extracellular matrix reconstruction — it rebuilds the structural scaffolding that other repair processes depend on. Research has also documented its ability to reset gene expression in damaged tissue toward a more youthful, regenerative state via broad epigenetic modulation.
BPC-157 (Body Protection Compound)
BPC-157 is a 15-amino-acid synthetic peptide derived from a protective protein found in gastric juice. It is one of the most extensively studied peptides in musculoskeletal and connective tissue repair research, with over two decades of preclinical literature documenting its effects on tendons, ligaments, bone, muscle, and gut epithelium.
Its primary mechanisms include upregulation of vascular endothelial growth factor receptor-2 (VEGFR2), which drives angiogenesis and accelerates blood supply restoration to injured tissue; direct stimulation of fibroblast migration and proliferation at injury sites; and interaction with the nitric oxide (NO) system to modulate vascular tone and reduce ischaemia-reperfusion injury. BPC-157 is unusual among repair peptides in that it shows comparable efficacy whether administered locally or systemically, and its effects extend to ligament-to-bone healing — one of the slowest and most difficult repair processes in musculoskeletal medicine.
TB-500 / Thymosin Beta-4 (TB4)
Thymosin Beta-4 (the active peptide; TB-500 is the commercially synthesised fragment) is a 43-amino-acid protein encoded by the TMSB4X gene and is one of the most abundant intracellular peptides in mammalian tissue. Its primary biological function is G-actin sequestration — it binds monomeric actin and regulates the pool available for polymerisation into the filaments that drive cell migration, wound closure, and tissue remodelling.
Beyond its structural role in actin dynamics, TB4 exerts systemic anti-inflammatory effects through downregulation of NF-κB signalling and reduction of pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. Its molecular weight and distribution pattern through the lymphatic system give it a systemic reach that local-acting peptides like BPC-157 cannot replicate. In recovery research, TB4 is particularly valued for injuries at sites difficult to reach with local injection — the spine, deep tendons, and central connective tissue structures. It also promotes cardiomyocyte survival and repair, making it of interest in cardiac recovery research.
KPV (Lys-Pro-Val)
KPV is a C-terminal tripeptide fragment of alpha-MSH (alpha-melanocyte-stimulating hormone), specifically the last three amino acids (Lys-Pro-Val) that carry most of its anti-inflammatory bioactivity. Alpha-MSH is a well-characterised endogenous anti-inflammatory neuropeptide; KPV retains this activity in a shorter, more stable form.
KPV acts primarily by inhibiting NF-κB nuclear translocation and downstream transcription of pro-inflammatory cytokines. Crucially, it achieves this through a different receptor pathway than TB4 — KPV engages the melanocortin receptor system, while TB4's NF-κB inhibition is primarily cytosolic. This mechanistic non-redundancy means both compounds contribute independently to inflammation resolution. KPV has also demonstrated direct intestinal epithelial protective effects, making it particularly valuable in gut-inflammation research models and suggesting broader mucosal recovery applications.
Why Stack These Peptides Together?
The case for the Klow Blend's four-compound formulation is mechanistic complementarity across the entire tissue repair timeline. Acute recovery research typically identifies three overlapping phases: the inflammatory phase (0–72 hours), the proliferative phase (days 3–21), and the remodelling phase (weeks 3–12+). No single peptide addresses all three phases with equal depth.
KPV and TB4 both attenuate the inflammatory phase, but via independent receptor systems (melanocortin vs. cytosolic NF-κB suppression), providing dual-pathway inflammation control that research suggests is more complete than either alone. BPC-157 bridges the inflammatory and proliferative phases by initiating fibroblast recruitment and angiogenesis while inflammation is still resolving. GHK-Cu then sustains the proliferative and remodelling phases, rebuilding the extracellular matrix and upregulating the growth factors required for structural tissue restoration.
The systemic versus local coverage is also complementary: TB4's lymphatic distribution provides body-wide anti-inflammatory and migration support, while BPC-157 and GHK-Cu work most efficiently at or near the site of interest. KPV's gut-epithelial protection adds a further layer relevant to systemic inflammation driven by intestinal permeability — a frequently overlooked component of chronic recovery impairment.
For researchers studying comprehensive recovery, this mechanistic layering means the Klow Blend addresses targets that a simple BPC-157 + TB-500 stack does not: the upstream copper-dependent matrix synthesis (GHK-Cu) and the melanocortin anti-inflammatory axis (KPV). The result is a more complete coverage of the recovery biology with a single, pre-verified product.
Dosage Protocol
Because the Klow Blend contains four peptides in a fixed ratio within an 80mg vial, dosing is governed by the blend's composition and the total vial content. Researchers should refer to the individual compound dosing literature for guidance on proportional allocation:
- BPC-157: Typically studied at 250–500 mcg per day in preclinical models
- TB-500 / TB4: Typically studied at 2–2.5 mg twice weekly (loading phase), then 2 mg weekly (maintenance)
- GHK-Cu: Typically studied at 1–2 mg per day subcutaneous
- KPV: Typically studied at 400–800 mcg per day
All components require reconstitution with bacteriostatic water prior to use. Use the BAC water reconstitution calculator to calculate the precise diluent volume for your target concentration given the blend's total peptide content. Store lyophilised powder at -20°C; reconstituted solution at 4°C and use within 28 days.
Given the multi-compound nature of the blend, protocol design should account for the TB4 component's twice-weekly schedule, which is typically the rate-limiting dosing frequency in a combined recovery stack.
Who Is the Klow Blend For?
The Klow Blend is designed for researchers conducting comprehensive recovery studies where multiple repair axes need to be addressed simultaneously. The single-vial format is particularly suited to research designs where protocol simplicity is a priority — avoiding the reconstitution, labelling, storage, and dosing logistics of managing four separate peptide vials reduces the operational overhead of complex multi-compound protocols.
It is appropriate for research into: musculoskeletal injury recovery (tendon, ligament, muscle, and bone); post-surgical soft tissue repair; systemic inflammation resolution; gut mucosal recovery; and dermal remodelling studies where GHK-Cu's skin collagen and matrix effects are relevant. The presence of KPV and TB4 also makes it suitable for research into chronic inflammatory conditions where multiple cytokine pathways require simultaneous suppression.
Researchers studying individual compound dose-response relationships should note that the fixed-ratio blend format means the doses of all four peptides scale together — it is not suited to protocols requiring independent titration of each component. For those research designs, the individual peptides (available separately in our recovery peptides collection) offer greater flexibility.
Where to Buy the Klow Blend in India
Peptide Central stocks the Klow Blend at 99% HPLC-verified purity with a full Certificate of Analysis included with every order. The 80mg vial is available at ₹6,999 (originally ₹11,999), representing over 40% savings versus the standard price. Pan-India delivery with Cash on Delivery (COD), UPI, and IMPS payment options available. Same-day dispatch confirmation via WhatsApp.
For researchers who prefer to source the individual components, GHK-Cu, BPC-157, TB-500, and KPV are each available separately in our recovery peptides collection at the same 99% purity standard.